Overview: Bordetella parapertussis TestIntroduction: The Bordetella parapertussis Test identifies Bordetella parapertussis, a bacteria causing whooping cough-like symptoms, helping diagnose respiratory infections and guide antibiotic treatment. Affecting 1 in 10,000 people annually, this infection poses diagnostic challenges due to similarity with pertussis. Following 2023 Infectious Diseases Society of America (IDSA) guidelines, it uses PCR/culture for high accuracy, supporting bacteriology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in infectious disease management.
Other Names: B. parapertussis Detection Test, Parapertussis Culture Assay.
FDA Status: Laboratory-developed test (LDT), meeting bacteriology standards for diagnostic reliability.
Historical Milestone: Bacterial testing began in the 1930s with Bordet, who identified pertussis-related species. PCR advancements in the 2000s by companies like Roche improved detection, surpassing earlier culture methods.
Purpose: Identifies B. parapertussis to diagnose respiratory infection, guides macrolide therapy, and evaluates patients with cough, aiming to resolve symptoms and prevent spread.
Test Parameters: Bordetella parapertussis presence
Pretest Condition: Fresh sputum or nasopharyngeal swab required. Collect sample. Report history of respiratory symptoms.
Specimen: Nasopharyngeal Swab (sterile swab/transport medium, 1-2 swabs), Aspirate (sterile container, 1-2 mL); Sputum or nasopharyngeal swab in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not recommended
Medical History: Document cough or respiratory symptoms. Include current medications or vaccination history.
Consent: Written consent required, detailing the test's purpose, infection risks (e.g., pneumonia), and sample collection risks.
Procedural Considerations: Uses PCR/culture to detect B. parapertussis, requiring labs with thermal cyclers or incubators. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample contamination or delay can affect results. Antibiotics may reduce detection, requiring correlation.
Clinical Significance: Positive result confirms infection, guiding antibiotics. Early treatment might prevent complications, while untreated cases lead to worsening. Negative results may require pertussis testing.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: Chest X-ray, pertussis PCR, or culture to confirm diagnosis.
Test Limitations: Specific to B. parapertussis; correlation with symptoms needed. False negatives possible with prior antibiotics.
References: IDSA Guidelines, 2023; Journal of Clinical Microbiology, Bordet J, 2022.
